Gland Pharma is one of the fastest growing generic injectables-focused companies, selling its products primarily under a business to business (B2B) model in over 60 countries including the United States, Europe, Canada, Australia, India and the Rest of the world.
Gland Pharma Company was established in Hyderabad, India in 1978 and has a professional management team and one of our Promoters, Shanghai Fosun Pharma, is a global pharmaceutical major.
Gland Pharma have a professional management team and one of the Promoters, Shanghai Fosun Pharma, is a global pharmaceutical major.
Gland Pharma has seven manufacturing facilities in India, comprising four finished formulations facilities with a total of 22 production lines and three API facilities.
As of March 31, 2020, it had manufacturing capacity for finished formulations of approximately 755 million units per annum.
As of March 31, 2020, Gland Pharma along with its partners had 265 ANDA filings in the United States, of which 204 were approved and 61 were pending approval.
The 265 ANDA filings comprise 189 ANDA filings for sterile injectables, 50 for oncology and 26 for ophthalmics related products.
Company Strengths
- The extensive product portfolio of complex injectables.
- Diversified B2B model with a targeted B2C model in India.
- Strong manufacturing capabilities.
- Robust financial track record.
- Experienced and qualified managerial team.
Company Financials
| For the year/period ended (₹ in million) | |||
| Particulars | 31-Mar-20 | 31-Mar-19 | 31-Mar-18 |
| Total Assets | 40,860.39 | 35,235.49 | 29,294.68 |
| Total Revenue | 27,724.08 | 21,297.67 | 16,716.82 |
| Profit After Tax | 7,728.58 | 4,518.56 | 3,210.51 |
Objects Of The Issue
The proceeds of the IPO will be used for the following purposes:
- To finance the growing operating costs of our Company
- To meet the financial requirements of the capital expenditure requirements
- Meeting common cooperative goals
Gland Pharma IPO Details
| IPO Open Date | 09 NOV 2020 |
| IPO Close Date | 11 NOV 2020 |
| Issue Type | Book Built Issue IPO |
| Issue Size | ₹ 6480 Cr |
| Offer for Sale | 34,863,635 Equity Share |
| Face Value | ₹1 Per Equity Share |
| IPO Price | [1490] to [1500] per equity share |
| Market Lot | 10 Shares |
| Min Order Quantity | 10 Shares |
| Listing At | BSE, NSE |
Gland Pharma IPO – Schedule
| Bid/Offer Opens On | 09 NOV 2020 |
| Bid/Offer Closes On | 11 NOV 2020 |
| Finalisation of Basis of Allotment | 17 NOV 2020 |
| Initiation of Refunds | 18 NOV 2020 |
| Credit of Shares to Demat Acct | 19 NOV 2020 |
| IPO Shares Listing Date | 20 NOV 2020 |
Gland Pharma IPO Lot Size and Price (Retail)
| Application | Lots | Shares | Amount (Cut-off) |
|---|---|---|---|
| Minimum | 1 | 10 | ₹15,000 |
| Maximum | 13 | 130 | ₹1,95,000 |
Gland Pharma IPO: How To Apply
Promoters play a very important role in raising much-needed business revenue.
Apply For Gland Pharma IPO Through ASBA
First, you should know what ASBA is. ASBA stands for Restricted Application Support. It is an application by the bank to apply for an IPO.
You apply with ASBA through the bank because initially, the bank covers the cost of purchasing the IPO. This amount is deducted from your account only after receiving IPO share shares in your Demat account.
All the major banks in the country are expanding the ASBA center. There are about 30 banks on the list, some of which are IDBI Bank Limited, Citi Bank, Punjab National Bank, etc.
The center may be expanded once they have been authorized to do so. These banks block the corresponding amount until the IPO allocation process is finalized.
Now, most of you are probably thinking about how to use the Gland Pharma IPO with ASBA. The process can be completed online or offline for your convenience.
Apart from this, you can also bid for an Gland Pharma IPO through your stockbroker’s online portal (such as Zerodha, Edelweiss, Motilal Oswal, etc.)
Company Contact Information
| Gland Pharma Limited Sy. No. 143 – 148, 150 and 151, Near Gandi Maisamma ‘X’ Roads, D.P. Pally,Dundigal Medchal-Malkajgiri District, Hyderabad Phone: +91 40 3051 0999 Email: investors@glandpharma.com Website: http://www.glandpharma.com |
